MindMed believes tripping could be big business

By Alma Fabiani

Published May 3, 2021 at 09:39 AM

Reading time: 2 minutes

“We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies. Together we can overcome,” reads MindMed’s website. The company is known for discovering, developing, and deploying psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering in patients. And that’s not all, on Tuesday 27 April, the biotech company went public on the Nasdaq exchange under the ticker “MNMD.” Here’s how MindMed hopes to capture shares of those markets with its alternative, psychedelic offerings.

After its Nasdaq listing debut on Tuesday, MindMed became the latest psychedelic drug developer to use a major US exchange as a pathway to raise money and bring new mental illness and addiction treatments deeper into the mainstream. This listing means the stock now trades on the Nasdaq Capital Market as well as on the NEO Exchange in Canada.

“Shares surged 33 per cent over the counter on Monday ahead of Tuesday’s listing,” reported Investor’s Business Daily. But things didn’t exactly go to plan—in a public market where stocks can do no wrong, MindMed got torched by close, dropping as much as 30 per cent.

That didn’t stop CEO JR Rahn to stay hopeful about the future of the stock listing, who said in a statement that it would “increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.”

And MindMed’s future does seem interesting. The biotech company is working on an array of projects from LSD’s impact on anxiety and ADHD to a compound it calls 18-MC (a non-hallucinogenic synthetic derivative of ibogaine that is in trials for addiction treatment).

And according to an investor deck, industry stats are all good trips to get on. The global antidepressants market is expected to grow colossally in the next few years, from anxiety and ADHD drugs to depression and anti-addiction treatments.

Like many other psychedelic drug companies, none of MindMed’s major projects has generated revenue or profit yet. In a March filing, the company said it expects operating losses to continue and that it expects to incur “significant costs associated with its research and development initiatives.”

It makes sense then that it is looking for opportunities to garner more attention and money. Now, the question is: is the stock a risky buy currently? Although the global psychedelic drugs market has grown significantly in recent years due to an increasing prevalence of mental disorders, depression, and breakthroughs relating to psychedelic drugs, the market still faces considerable risk and uncertainties before it can secure the US’ FDA approvals.

On top of that, the stigma associated with the use of psychedelic drugs is also a big burden. As of now, the psychedelic drugs market remains at an early developmental stage, with most companies still executing clinical trials. This could hinder MindMed’s growth in the near term. “Although its pipeline projects look promising, there remains high uncertainty regarding its commercial prospects and value,” writes Entrepreneur.

The stock soared 773.9 per cent over the past year, mainly because of a surge in the popularity of psychedelic drugs. That being said, uncertainties regarding a timeline for potential FDA approval of its therapies could mean danger ahead. That’s why it would be wise to avoid the stock and simply enjoy psychedelics as a recreational drug for now. Looks like MindMed is about to go on a bad trip…

Keep On Reading

By Abby Amoakuh

Mainstream media’s criticism of 9 to 5 girl is proof that boomers will always be out to get gen Z

By Abby Amoakuh

RuPaul’s new online bookstore Allstore removes anti-trans and far-right books following controversy

By Fatou Ferraro Mboup

What is legal cocaine? And how is it now being incorporated into our food and drinks?

By Charlie Sawyer

Ron DeSantis’ administration links pro-Palestine student group to terrorism and bans it from campus

By Emma O'Regan-Reidy

Is the end of Airbnb near? Two subreddits point to an impending flop

By Bianca Borissova

What is the girlfriend effect? Inside the TikTok trend improving men’s style

By Charlie Sawyer

Top Captain Holt moments from Brooklyn Nine-Nine that will make us miss Andre Braugher

By Charlie Sawyer

How to get a refund on your student loan from SLC

By Charlie Sawyer

Nikki Haley snaps at Fox News reporters who asked her why she hasn’t dropped out of the election

By Charlie Sawyer

M&S pulls Christmas advert post of burning hats after being called out by pro-Palestine supporters

By Abby Amoakuh

Two Australian OnlyFans stars slammed for recruiting high schoolers for explicit content

By Abby Amoakuh

Video of Donald Trump accusing Barack Obama of founding ISIS goes viral days after Moscow attack

By Charlie Sawyer

OnlyFans models are using breastfeeding content as a loophole to bypass Instagram’s nudity policy

By Abby Amoakuh

Drake calls for release of Tory Lanez, proving once more that he’s a rapper for the manosphere

By Abby Amoakuh

Sydney Sweeney’s boobs have feminists divided: Where does liberation start and objectification end?

By Abby Amoakuh

What is girl ethics? The gen Z-improved TikTok version of the girl code

By Charlie Sawyer

6 easy hacks to slay no spend January this year

By Fatou Ferraro Mboup

Netflix’s depiction of Griselda Blanco was wrong. Why the cocaine godmother was not a feminist icon

By Charlie Sawyer

Donald Trump warns of chaos and bedlam if his name is kept off the US presidential election ballot

By Lois Freeman

From war zones to fashion runways: Model agencies exposed for recruiting women in refugee camps